Effect of vildagliptin combined with insulin aspart 30 injection on islet β-cell function and serum HbA1c and VASPIN levels in obese type 2 diabetic patients
LI Rui1, JIN Xiaona1, ZHANG Dangfeng2
1. Department of medical, Xi’an International University, Xi an 710077, China; 2. Department of Orthopaedics, the First Affiliated Hospital, Xi’an Jiaotong University, Xi an 710061,China
Abstract：Objective To investigate the effect of vildagliptin + insulin aspart 30 injection on islet β-cell function, serum glycosylated hemoglobin (HbA1c) and vaginal adipose tissue-derived serine protease inhibitor (VASPIN) in obese type 2 diabetic patients.Methods A total of 157 patients with obese type 2 diabetes mellitus treated between March 2017 and July 2018 were enrolled in this study. Using the random number table method, these patients were divided into the control group (n=78) and study group (n=79). The control group was injected with insulin aspart 30, while the study group was additionally treated with vildagliptin. The course of treatment was 12 weeks. The curative effect and rate of adverse reactions were compared between the two groups. The fasting blood glucose (FPG), postprandial 2 h blood glucose (2 h PG), HbA1c, islet β cell secretory index (HOMA-β) and VASPIN levels before and after treatment were compared.Results (1) The ideal rate of HbA1c control in the study group was higher than that in the control group (P<0.05). (2) The levels of FPG, 2 h PG and HbA1c in the two groups were lower after treatment, especially in the study group (P<0.05). (3) The levels of serum HOMA-β and VASPIN in the two groups were higher after treatment, particularly in the study group (P<0.05). (4) The total incidence of adverse reactions in the study group was 5.06%, which was not significantly different from the control group (2.56%) (P>0.05).Conclusions The treatment of obese type 2 diabetic patients with vildagliptin + insulin aspart 30 injection is obviously effective, which can improve their blood glucose and serum VASPIN levels, protect islet β cell function, and reduce the incidence of hypoglycemia.
李蕊, 金晓娜, 张党锋. 维格列汀联合门冬胰岛素30注射液对肥胖型2型糖尿病患者胰岛β细胞功能及血清糖化血红蛋白水平的影响[J]. 武警医学, 2019, 30(6): 499-502.
LI Rui, JIN Xiaona, ZHANG Dangfeng. Effect of vildagliptin combined with insulin aspart 30 injection on islet β-cell function and serum HbA1c and VASPIN levels in obese type 2 diabetic patients. Med. J. Chin. Peop. Armed Poli. Forc., 2019, 30(6): 499-502.
Pan C,Xing X,Han P,et al.Efficacy and tolerability of vild agliptin as add - on therapy to metforminin Chinese patients with type 2diabetes mellitus[J].Diabetes Obes Metab,2012,14(8):737-744.
Derosa G,Maffioli P. Efficacy and safety profile evaluation of acarbose alone and in association with other antidiabetic drugs: asystematic review[J].Clin Ther,2012,34(6):1221-1236.
Su J B,Wang X Q,Chen J F,et al.Glycemic variability in insulin treated type 2 diabetes with well-controlled hemoglobin A1c and its response to further treatment with acarbose[J].Chin Med J(Engl),2011,124(1):144-147.
Choe E Y,Cho Y,Choi Y,et al.The effect of DPP-4 inhibitors on metabolic parameters in patients with type 2 diabete[J].Diabetes Metab J,2014,38(3):211-219.
Strain W D,Lukashevich V,Kothny W,et al.Individualised treatment targets for elderly patients with type 2 diabetes using vildagliptin add-on or lone therapy(INTERVAL):a 24 week, randomised, doubleblind,placebo-controlled study[J].Lancet,2013,382(9890):409-416.
2019, Vol. 30 
